TY - JOUR
T1 - Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer
AU - Richardson, Debra L.
AU - Backes, Floor J.
AU - Seamon, Leigh G.
AU - Zanagnolo, Vanna
AU - O'Malley, David M.
AU - Cohn, David E.
AU - Fowler, Jeffrey M.
AU - Copeland, Larry J.
PY - 2008/12
Y1 - 2008/12
N2 - Objective: To describe the response rate (RR), progression-free survival (PFS), and toxicity profile of combination gemcitabine, platinum, and bevacizumab (GPB) for the treatment of recurrent epithelial ovarian cancer (EOC). Methods: A chart review of all patients with recurrent EOC who were treated with D1, D15 GPB in a 28-day cycle at a single institution was performed. Standard doses were gemcitabine 1000 mg/m2, cisplatin 30 mg/m2 or carboplatin AUC 3, and bevacizumab 10 mg/kg. All patients were analyzed for toxicity. RR and PFS were assessed in all patients who received at least 2 cycles of GPB. Results: Thirty-five patients were identified, and 33 received at least 2 cycles of GPB. The majority of patients (80%) were platinum sensitive. Patients received a median of 6 cycles of GPB (range 1-24). Sixteen patients (48%) had a complete response (CR), and 10 patients (30%) had a partial response (PR), for a total RR of 78%. An additional 5 patients (15%) had stable disease, and only 2 (6%) patients had progressive disease. The median overall PFS was 12 months (95% CI 7-15), with a median follow-up time of 10 months (2-22). Two patients (6%) had bowel perforations, and both survived. Hematologic toxicities were most common, with 29% and 14% of patients experiencing grade 3 or 4 neutropenia and thrombocytopenia respectively. Conclusions: The combination of GPB demonstrated excellent efficacy for the treatment of recurrent EOC. However, serious toxicities occurred, and the safety profile of this combination requires further study.
AB - Objective: To describe the response rate (RR), progression-free survival (PFS), and toxicity profile of combination gemcitabine, platinum, and bevacizumab (GPB) for the treatment of recurrent epithelial ovarian cancer (EOC). Methods: A chart review of all patients with recurrent EOC who were treated with D1, D15 GPB in a 28-day cycle at a single institution was performed. Standard doses were gemcitabine 1000 mg/m2, cisplatin 30 mg/m2 or carboplatin AUC 3, and bevacizumab 10 mg/kg. All patients were analyzed for toxicity. RR and PFS were assessed in all patients who received at least 2 cycles of GPB. Results: Thirty-five patients were identified, and 33 received at least 2 cycles of GPB. The majority of patients (80%) were platinum sensitive. Patients received a median of 6 cycles of GPB (range 1-24). Sixteen patients (48%) had a complete response (CR), and 10 patients (30%) had a partial response (PR), for a total RR of 78%. An additional 5 patients (15%) had stable disease, and only 2 (6%) patients had progressive disease. The median overall PFS was 12 months (95% CI 7-15), with a median follow-up time of 10 months (2-22). Two patients (6%) had bowel perforations, and both survived. Hematologic toxicities were most common, with 29% and 14% of patients experiencing grade 3 or 4 neutropenia and thrombocytopenia respectively. Conclusions: The combination of GPB demonstrated excellent efficacy for the treatment of recurrent EOC. However, serious toxicities occurred, and the safety profile of this combination requires further study.
KW - Bevacizumab
KW - Bowel perforation
KW - Gemcitabine
KW - Platinum
KW - Recurrent epithelial ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=56449105264&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56449105264&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2008.08.011
DO - 10.1016/j.ygyno.2008.08.011
M3 - Article
C2 - 18829088
AN - SCOPUS:56449105264
SN - 0090-8258
VL - 111
SP - 461
EP - 466
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 3
ER -